This week, 7 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Prestige Brands Holdings, Inc.’s (PBH) rating worsens to a D from the company’s C rating a week ago. Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PBH stock.
Slipping from a D to a F rating, Teva Pharmaceutical Industries Limited Sponsored ADR (TEVA) takes a hit this week. Teva Pharmaceutical Industries Limited Sponsored ADR is engaged in the provision of pharmaceutical services. The company also gets F’s in earnings growth. For more information, get Portfolio Grader’s complete analysis of TEVA stock.
This is a rough week for Mylan N.V. (MYL). The company’s rating falls to D from the previous week’s C. Mylan N.V. is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.
This week, Intra-Cellular Therapies, Inc. (ITCI) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.
Omeros Corporation (OMER) declines this week from a C to a D. Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.
Ocular Therapeutix Inc (OCUL) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCUL stock.
DURECT Corporation (DRRX) gets weaker ratings this week as last week’s D drops to a F. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
